drugset / Trial / NCT03709745

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

NCT03709745

Phase 4 Completed 110 enrolled St. Erik Eye Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Comparing time to recurrence of macular edema after an initial loading dose of at least three monthly anti VEGF injections (aflibercept or ranibizumab) for macular edema in BRVO.

Timeline

Start
2018-10-18
Primary completion
2021-10-15
Completion
2022-07-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic Intravitreal
Comparator Ranibizumab Monoclonal antibody Intravitreal